The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism

Lipids in Health and Disease

Stanislav Oravec³  Zuzana Celecová⁴  Peter Kruzliak¹  Ludovit Gaspar²  Zuzana Minarikova² 

[1] Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne’s University Hospital and Masaryk University, Pekarska 53, Brno 656 91, Czech Republic;2nd Department of Internal Medicine, Faculty of Medicine, University Hospital and Comenius University, Bratislava, Slovak Republic;Krankenanstalten Labor Dr. Dostal, Vienna, Austria;Department of Internal Medicine, Hospital of L. N. Jégé, M.D, Dolný Kubín, Slovakia

关键词: Atherogenic index of plasma;    apoB;    Small dense LDL;    Hypothyroidism;    Atherogenic dyslipidemia;   

Others  :  1151821
DOI  :  10.1186/1476-511X-13-158

 received in 2014-07-30, accepted in 2014-10-01,  发布年份 2014

【 摘 要 】

Background

Atherogenic dyslipoproteinemia is one of the most important risk factor for atherosclerotic changes development. Hypothyroidism is one of the most common causes of secondary dyslipidemias which results from reduced LDL clearance and therefore raised levels of LDL and apoB. Association between small dense LDL (sdLDL) presentation and thyroid status has been examinated using polyacrylamide gel electrophoresis for lipoprotein subfractions evaluation.

Methods

40 patients with diagnosed autoimmune hypothyroidism and 30 patients with autoimmune hyperthyroidism were treated with thyroxine replacement or thyreo-suppressive treatment. In both groups lipid profiles, LDL subractions, apolipoproteins (apoA1, apoB), apoA1/apoB ratio and atherogenic index of plazma (AIP) were examined before treatment and in state of euthyreosis.

Results

Thyroxine replacement therapy significantly reduced levels of total cholesterol (TC), LDL, triglycerides (TG) and also decreased levels of sdLDL (8,55±11,671 vs 0,83±1,693mg/dl; p<0,001), apoB and AIP. For estimation of atherogenic lipoprotein profile existence an AIP evaluation seems to be better than apoB measurement because of the more evident relationship with sdLDL (r=0,538; p<0,01). Thyreo-suppressive therapy significantly increased levels of TC, LDL, TG and apoB. The sdLDL was not found in hyperthyroid patients.

Conclusions

Atherogenic lipoprotein profile was present in 52.5% of hypothyroid subjects, which is higher prevalence than in normal, age-related population. Substitution treatment leads to an improvement of the lipid levels, TG, apoB, AIP and LDL subclasses. It significantly changed the presentation of sdLDL – we noticed shift to large, less atherogenic LDL particles. Significantly positive correlation between sdLDL and TAG; sdLDL and VLDL alerts to hypertriglyceridemia as a major cardiovascular risk factor.

【 授权许可】

   
2014 Minarikova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Rizzo M, Berneis K: Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006, 99:1-14.
• [2]Fisher WR: Heterogenity of plasma low density lipoproteins: manifestation of the physiologic phenomenon in man. Metabolism 1983, 32:283-291.
• [3]Lamarche B, Lemieux I, Despres JP: The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999, 25:199-211.
• [4]Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP: Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart Disease in men. Prospective results from the Quebec Cardiovascular study. Circulation 1997, 95:69-75.
• [5]Sacks FM, Campos H: Clinical review 163: Cardiovascular endocrinology 4: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003, 88:4525-4532.
• [6]Annonymous: Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
• [7]Berneis KK, Kraus RM: Metabolic origins and clinical significance of LDL heterogenity. J Lipid Res 2002, 43:1363-1379.
• [8]Rizzo M, Berneis K, Corrado E, Novo S: The significance of low-density-lipoproteins size in vascular disease. Int Angiol 2006, 25:4-9.
• [9]Nielsen LB: Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 1996, 123:1-15.
• [10]Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ: Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol 1997, 17:2507-2514.
• [11]Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
• [12]Krauss RM: Atherogenic lipoprotein phenotype and diet-gene interactions. J Nutr 2001, 131:340S-343S.
• [13]Rizzo M, Berneis K: Should we measure routinely the LDL peak particle size. Int J Cardiol 2006, 107:166-170.
• [14]Maki KC, Davidson MH, Marx P, Cyrowski MS, Maki A: Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am J Cardiol 2000, 85:451-456.
• [15]Festa A, D'Agostino R Jr, Mykkanen L, Tracy R, Howard BV, Haffner SM: Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 1999, 19:605-610.
• [16]Jellinger PS, Dickey RA, Ganda OP, Mehta AE, Nguyen TT, Rodbard HW, Seibel JA, Shepherd MD, Smith DA: The american association of clinical endocrinologists, medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract 2000, 6:162-204.
• [17]Packard CJ: Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003, 31(pt5):1066-1069.
• [18]Roscini AR, Lupattelli G, Siepi D, Pagliaricci S, Pirro M, Mannarino E: Low-density lipoprotein size in primary hypothyroidism. Effects of hormone replacement therapy. Ann Nutr Metab 1999, 43:374-379.
• [19]Abbas JMK, Chakraborty J, Akanji AO, Doi SAR: Hypothyroidism results in small dense LDL independent of IRS Traits and hypertriglyceridemia. Endocr J 2008, 55:381-389.
• [20]Kim CS, Kang JG, Lee SJ, Ihm SH, Yoo HJ, Nam JS, Ahn CW, Kim KR: Relationship of low-density lipoprotein (LDL) particle size to thyroid function status in Koreans. Clin Endocrinol (Oxf) 2009, 71:130-136.
• [21]Duntas LH, Brenta G: The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012, 96:269-281.
• [22]Ittermann T, Baumeister SE, Völzke H, Wasner C, Schminke U, Wallaschofski H, Nauck M, Lüdemann J: Are serum TSH levels associated with oxidized low-density lipoprotein? Results from the Study of Health in Pomerania. Clin Endocrinol (Oxf) 2012, 76:526-532.
• [23]Regmi A, Shah B, Rai BR, Pandeya A: Serum lipid profile in patients with thyroid disorders in central Nepal. Nepal Med Coll J 2010, 12:253-256.
• [24]Teixeira Pde F, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Buescu A, Costa AJ, Vaisman M: Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Transl Res 2008, 151:224-231.
• [25]Dobiasova M, Frohlich J: The plasma parameter Log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo-B-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001, 34:583-588.
• [26]Dobiasova M: Atherogenic index of plasma [Log (Triglycerides/HDL-Cholestrol)]: Theoretical and practical implications. Clin Chem 2004, 50:1113-1115.
• [27]Rainwater DL, Moore PH, Shelledy WR, Dyer TD, Slifer SH: Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res 1997, 38:1261-1266.
• [28]Hirano T, Ito Y, Yoshino G: Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 2005, 12:67-72.
• [29]Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM: Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
• [30]Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [31]Hoefner DM, Hodel SD, O’Brien JF, Branum EL, Sun D, Meissner I, McConnell JP: Development of a rapid quantitative method for LDL subfraction with use of the Quantimetrix Lipoprint LDL system. Clin Chem 2001, 47:266-274.
• [32]Hirany SV, Othman Y, Kutscher P, Rainwater DL, Jialal I, Devaraj S: Comparison of low-density lipoprotein size by polyacrylamide tube gel electrophoresis and polyacrylamide gradient gel electrophoresis. Am J Clin Pathol 2003, 119:439-445.
• [33]Ensign W, Hill N, Heward CB: Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 2006, 52:1722-1727.
• [34]Van J, Pan J, Charles MA, Krauss R, Wong N, Wu X: Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007, 131:1679-1685.
• [35]Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.
• [36]Austin MA, Hokanson JE, Brunzell JD: Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994, 5:395-403.
• [37]Fruchart JCH, Sacks FM, Hermans MP, Assman G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008, 5:319-335.
• [38]Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL: Lippoproteins and diabetic microvascular complications. Curr Pharm Des 2004, 10(27):3395-3418.
• [39]Assmann G: Dyslipidemia and global cardiovascular risk: clinical issues. Eur Heart J Suppl 2006, 8(Suppl F):F40-46.
• [40]Kato M, Dote K, Sasaki S, Ueda K, Kono Y, Naganuma T, Watanabe Y, Kajikawa M, Yokoyama H, Higashi A: Clinical impact of dyslipidemia for coronary plaque vulnerability in acute coronary syndrome without metabolic syndrome. J Cardiol 2009, 54:394-401.
• [41]St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Després JP, Lamarche B: Low-density-lipoprotein subfraction and the long-therm risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005, 25:553-559.
• [42]Jiskra J, Limanovi Z, Antosova M: Thyroid diseases, dyslipidemia and cardiovascular risk. Vnitr Lek 2007, 53:382-385.
• [43]Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC: Subclinical hypothyreoidism is an independent risk factor for atherosclerosis and myocardial infarction in erderly women: the Rotterdam Study. Ann Intern Med 2000, 132:270-278.
• [44]Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, Ashizawa K, Yokoyama N, Maeda R, Nagataki S, Eguchi K: Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004, 89:3365-3370.
• [45]Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V: Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005, 165:2467-2472.
• [46]Wanjia X, Chenggang W, Aihong W, Xiaomei Y, Jiajun Z, Chunxiao Y, Jin X, Yinglong H, Ling G: A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease. Lipids Health Dis 2012, 11:44. BioMed Central Full Text
• [47]Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
• [48]Oravec S, Gruber K, Dostal E, Mikl J: Hyper-betalipoproteinemia LDL 1,2: A newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuro Endocrinol Lett 2011, 32:322-327.
• [49]Castelli WP: Cholesterol and lipids in the risk of coronary artery disease – The Framingham Heart Study. Can J Cardiol 1988, 4(Suppl A):5A-10A.
• [50]Castelli WP: Epidemiology of triglycerides; a view from Framingham. Am J Cardiol 1992, 70:43-49.
• [51]Castelli WP: The new pathophysiology of coronary artery disease. Am J Cardiol 1998, 82(Suppl 2):60-85.
• [52]Tan MH, Johns D, Glazer NB: Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 2004, 50:1184-1188.
• [53]Brewer HB Jr: Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999, 83(9B):3F-12F.
• [54]Ooi EMM, Barrett PHR, Chan DC, Watts GF: Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci 2008, 114(10):611-624.
• [55]Zheng C, Khoo C, Furtado J, Sacks FM: Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Circulation 2010, 121(15):1722-1734.
• [56]Sniderman AD, Rosenbloom M: If apoB is so good, why isn’t everybody measuring it? One reason why we need The Netherlands Journal of Medicine! Neth J Med 2005, 63:232-235.
• [57]Albrink MJ, Man EB: Serum triglycerides in coronary artery disease. Arch Intern Med 1959, 103:4-8.
• [58]Sprecher DL: Triglycerides as a risk factor for coronary artery disease. Am J Cardiol 1998, 82:49U-56U.
• [59]Holewijn S, Sniderman AD, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J: Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study. Eur J Clin Invest 2011, 41:423-33.
• [60]Austin MA, King MC, Vranizan KM, Newman B, Krauss RM: Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 1988, 43:838-846.
• [61]Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, Castelli WP, Schaefer EJ: LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 1992, 12:1410-9.
• [62]Biondi B: How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism? Eur J Endocrinol 2012, 167:295-299.
• [63]Yang LB, Jiang DQ, Qi WB, Zhang T, Feng YL, Gao L, Zhao J: Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol 2012, 167:75-84.
• [64]Brandt F, Green A, Hegedüs L, Brix TH: A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 2011, 165:491-497.